Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Company Performance - Halozyme Therapeutics reported quarterly earnings of $1.54 per share, exceeding the Zacks Consensus Estimate of $1.23 per share, and up from $0.91 per share a year ago, representing an earnings surprise of +25.20% [1] - The company achieved revenues of $325.72 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 13.84%, compared to $231.35 million in the same quarter last year [2] - Over the last four quarters, Halozyme has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - Halozyme shares have increased approximately 25.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.45 on revenues of $327.83 million, and for the current fiscal year, it is $5.50 on revenues of $1.25 billion [7] - The outlook for the industry, specifically the Medical - Biomedical and Genetics sector, is currently in the bottom 43% of Zacks industries, which may impact stock performance [8]